Literature DB >> 18271938

Motif-programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria.

Hirohide Saito1, Tamiko Minamisawa, Takao Yamori, Kiyotaka Shiba.   

Abstract

By combinatorially assembling two natural motifs, respectively, associated with protein transduction (PTD) and induction of apoptosis (BH3), we previously synthesized an artificial protein (#284) that is taken up into cells, where it induces apoptosis. Here we used cluster analysis of GI(50) (average concentration required for 50% growth inhibition), as well as immunohistochemical and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling analyses to further characterize the capacity of #284 to induce apoptosis in a panel of 39 cancer cell lines. Our results showed that #284 preferentially inhibited the growth of several cancer cells with a GI(50) of approximately 5 microM, which is in the range of conventional anticancer drugs such as cisplatin and etoposide. In breast cancer HBC-4 cells, #284 caused mitochondrial aggregation and induced apoptosis in a BH3 motif-dependent manner. Moreover, transfection of the artificial gene that encodes #284 led to effective expression of the artificial protein within cells, which in turn caused apoptosis at a level similar to that seen in naturally occurring apoptosis inducers, Noxa/Bax transfectants. These findings suggest that synthetic proteins created by reprogramming peptide motifs have the potential to serve as novel agents useful in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18271938     DOI: 10.1111/j.1349-7006.2007.00697.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  1 in total

1.  Combinatorial contextualization of peptidic epitopes for enhanced cellular immunity.

Authors:  Masaki Ito; Kazumi Hayashi; Eru Adachi; Tamiko Minamisawa; Sadamu Homma; Shigeo Koido; Kiyotaka Shiba
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.